Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo

Kriste A. Lewis, Sarah A. Holstein, Raymond Hohl

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Lovastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase (HMGR), is used therapeutically to lower plasma cholesterol levels and has garnered attention for its cytotoxic effects in leukemia cells. In this study, escalating doses of lovastatin were administered to nine patients with acute myelogenous leukemia. Peripheral blood leukemia cells were drawn pre- and post-lovastatin dosing. Plasma lovastatin bioactivity ranged up to 234 nM lovastatin equivalents. Our results show that in vivo lovastatin, at up to 200 mg/dose, induces an increased activity of leukemia cell HMGR and alters leukemia cell proliferation without discernibly altering Ras processing.

Original languageEnglish (US)
Pages (from-to)527-533
Number of pages7
JournalLeukemia Research
Volume29
Issue number5
DOIs
StatePublished - Jan 1 2005

Fingerprint

Lovastatin
Biosynthetic Pathways
Terpenes
Acute Myeloid Leukemia
Leukemia
Oxidoreductases
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coenzyme A
Blood Cells
Cholesterol
Cell Proliferation

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{b125637894ea47c3894e1a2622787c04,
title = "Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo",
abstract = "Lovastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase (HMGR), is used therapeutically to lower plasma cholesterol levels and has garnered attention for its cytotoxic effects in leukemia cells. In this study, escalating doses of lovastatin were administered to nine patients with acute myelogenous leukemia. Peripheral blood leukemia cells were drawn pre- and post-lovastatin dosing. Plasma lovastatin bioactivity ranged up to 234 nM lovastatin equivalents. Our results show that in vivo lovastatin, at up to 200 mg/dose, induces an increased activity of leukemia cell HMGR and alters leukemia cell proliferation without discernibly altering Ras processing.",
author = "Lewis, {Kriste A.} and Holstein, {Sarah A.} and Raymond Hohl",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.leukres.2004.10.007",
language = "English (US)",
volume = "29",
pages = "527--533",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "5",

}

Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo. / Lewis, Kriste A.; Holstein, Sarah A.; Hohl, Raymond.

In: Leukemia Research, Vol. 29, No. 5, 01.01.2005, p. 527-533.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo

AU - Lewis, Kriste A.

AU - Holstein, Sarah A.

AU - Hohl, Raymond

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Lovastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase (HMGR), is used therapeutically to lower plasma cholesterol levels and has garnered attention for its cytotoxic effects in leukemia cells. In this study, escalating doses of lovastatin were administered to nine patients with acute myelogenous leukemia. Peripheral blood leukemia cells were drawn pre- and post-lovastatin dosing. Plasma lovastatin bioactivity ranged up to 234 nM lovastatin equivalents. Our results show that in vivo lovastatin, at up to 200 mg/dose, induces an increased activity of leukemia cell HMGR and alters leukemia cell proliferation without discernibly altering Ras processing.

AB - Lovastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase (HMGR), is used therapeutically to lower plasma cholesterol levels and has garnered attention for its cytotoxic effects in leukemia cells. In this study, escalating doses of lovastatin were administered to nine patients with acute myelogenous leukemia. Peripheral blood leukemia cells were drawn pre- and post-lovastatin dosing. Plasma lovastatin bioactivity ranged up to 234 nM lovastatin equivalents. Our results show that in vivo lovastatin, at up to 200 mg/dose, induces an increased activity of leukemia cell HMGR and alters leukemia cell proliferation without discernibly altering Ras processing.

UR - http://www.scopus.com/inward/record.url?scp=14744273421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14744273421&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2004.10.007

DO - 10.1016/j.leukres.2004.10.007

M3 - Article

VL - 29

SP - 527

EP - 533

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 5

ER -